| Original language | English |
|---|---|
| Pages (from-to) | E290-E293 |
| Journal | Haematologica |
| Volume | 105 |
| Issue number | 6 |
| DOIs | |
| State | Published - 1 Jun 2020 |
| Externally published | Yes |
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Haematologica, Vol. 105, No. 6, 01.06.2020, p. E290-E293.
Research output: Contribution to journal › Letter › peer-review
TY - JOUR
T1 - RNAmut
T2 - Robust identification of somatic mutations in acute myeloid leukemia using RNA-sequencing
AU - Gu, Muxin
AU - Zwiebel, Maximillian
AU - Ong, Swee Hoe
AU - Boughton, Nick
AU - Nomdedeu, Josep
AU - Basheer, Faisal
AU - Nannya, Yasuhito
AU - Quiros, Pedro M.
AU - Ogawa, Seishi
AU - Cazzola, Mario
AU - Rad, Roland
AU - Butler, Adam P.
AU - Vijayabaskar, M. S.
AU - Vassiliou, George S.
N1 - Funding Information: 1Haematological Cancer Genetics, Wellcome Sanger Institute, Hinxton, Cambridge, UK; 2Wellcome Trust–MRC Stem Cell Institute, Cambridge Biomedical Campus, University of Cambridge, Cambridge, UK; 3German Consortium for Translational Cancer Research (DKTK), Partnering Site, Munich, Germany; 4Cancer Ageing and Somatic Mutation, Wellcome Sanger Institute, Hinxton, Cambridge, UK; 5Core Software Services, Wellcome Sanger Institute, Hinxton, Cambridge, UK; 6Hospital de la Santa Creu I Sant Pau, Barcelona, Spain; 7Department of Haematology, Cambridge University Hospitals NHS Trust, Cambridge, UK; 8Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan and 9Fondazione IRCCS Policlinico San Matteo and University of Pavia, Pavia, Italy Correspondence: GEORGE VASSILIOU - [email protected] MS VIJAYABASKAR - [email protected] doi:10.3324/haematol.2019.230821 Funding: this project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 116026. This Joint Undertaking receives support from the European Union´s Horizon 2020 research and innovation and EFPIA. MG is funded by Horizon 2020 (No. 116026) and Cancer Research UK (C22324/A23015). GSV is funded by a Cancer Research UK Senior Cancer Research Fellowship (C22324/A23015) and work in his laboratory is also funded by the Wellcome Trust, European Research Council, Kay Kendall Leukaemia Fund, Bloodwise, The Leukemia Lymphoma Society and the Rising Tide Foundation for Clinical Cancer Research. MSV is funded by the Wellcome Trust (WT098051). The results shown here are in part based upon data generated by the TCGA Research Network: https://www.cancer.gov/tcga. Funding Information: This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 116026. This Joint Undertaking receives support from the European Unio?s Horizon 2020 research and innovation and EFPIA. MG is funded by Horizon 2020 (No. 116026) and Cancer Research UK (C22324/A23015). GSV is funded by a Cancer Research UK Senior Cancer Research Fellowship (C22324/A23015) and work in his laboratory is also funded by the Wellcome Trust, European Research Council, Kay Kendall Leukaemia Fund, Bloodwise, The Leukemia Lymphoma Society and the Rising Tide Foundation for Clinical Cancer Research. MSV is funded by the Wellcome Trust (WT098051). The results shown here are in part based upon data generated by the TCGA Research Network: https://www.cancer.gov/tcga.
PY - 2020/6/1
Y1 - 2020/6/1
UR - https://www.scopus.com/pages/publications/85085713932
U2 - 10.3324/haematol.2019.230821
DO - 10.3324/haematol.2019.230821
M3 - Letter
C2 - 31649132
AN - SCOPUS:85085713932
SN - 0390-6078
VL - 105
SP - E290-E293
JO - Haematologica
JF - Haematologica
IS - 6
ER -